Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction

Blood

Volumn 117, Issue 24, 2011, Pages 6694-6701

  De Willige, Shirley Uitte ^a   Miedzak, Megan ^a   Carter, Angela M ^a   Lisman, Ton ^b,c   Rosendaal, Frits R ^d   Grant, Peter J ^a   Philippou, Helen ^a   Ariëns, Robert A S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ARGININE; PLASMINOGEN; SERINE PROTEINASE INHIBITOR;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RISK FACTOR;

EID: 79959202075     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-320325     Document Type: Article

References (30)

1. van Gent D, Sharp P, Morgan K, Kalsheker N. Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol. 2003;35(11):1536-1547. (Pubitemid 36724947)
2. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978;84(2):573-578. (Pubitemid 8301289)
3. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976;251(19): 5956-5965.
4. Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976; 159(3):545-553.
5. Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem. 1982;257(24): 14767-14772. (Pubitemid 13159570)
6. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69(1):209-216.
7. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood. 2004;103(10):3783-3788. (Pubitemid 38596296)
8. Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem. 1989; 106(4):703-707. (Pubitemid 19241842)
9. Koyama T, Koike Y, Toyota S, et al. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun. 1994;200(1):417-422.
10. Christensen U, Clemmensen I. Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma. Biochem J. 1978; 175(2):635-641. (Pubitemid 9060122)
11. Wiman B. Affinity-chromatographic purification of human alpha 2-antiplasmin. Biochem J. 1980; 191(1):229-232. (Pubitemid 11198154)
12. Petersen LC, Clemmensen I. Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate the reaction with pancreatic trypsin-inhibitor and 2 forms of alpha-2-plasmin inhibitor. Biochem J. 1981;199(1):121-127. (Pubitemid 12198617)
13. Sasaki T, Morita T, Iwanaga S. Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor. J Biochem. 1986;99(6):1699-1705.
14. Wiman B, Nilsson T, Cedergren B. Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen. Thromb Res. 1982;28(2):193-199. (Pubitemid 13253527)
15. Sugiyama N, Sasaki T, Iwamoto M, Abiko Y. Binding site of alpha 2-plasmin inhibitor to plasminogen. Biochim Biophys Acta. 1988;952(1):1-7. (Pubitemid 18014080)
16. Sumi Y, Nakamura Y, Aoki N, Sakai M, Muramatsu M. Structure of the carboxyl-terminal half of human alpha 2-plasmin inhibitor deduced from that of cDNA. J Biochem. 1986;100(5):1399-1402.
17. Kluft C, Los P, Jie AF, et al. The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. Blood. 1986;67(3):616-622. (Pubitemid 16130247)
18. Clemmensen I, Thorsen S, Mullertz S, Petersen LC. Properties of three different molecular forms of the alpha 2 plasmin inhibitor. Eur J Biochem. 1981;120(1):105-112. (Pubitemid 12218966)
19. Tone M, Kikuno R, Kume-Iwaki A, Hashimoto-Gotoh T. Structure of human alpha 2-plasmin inhibitor deduced from the cDNA sequence. J Biochem. 1987;102(5):1033-1041.
20. Carter AM, Prasad UK, Grant PJ. Complement C3 and C-reactive protein in male survivors of myocardial infarction. Atherosclerosis. 2009; 203(2):538-543.
21. Hattey E, Wojta J, Binder BR. Monoclonal antibodies against plasminogen and alpha-2-antiplasmin: binding to native and modified antigens. Thromb Res. 1987;45(5):485-495. (Pubitemid 17047499)
22. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007;27(12):2783-2789. (Pubitemid 350158937)
23. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6): 715-722. (Pubitemid 40216041)
24. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010;116(1):113-121.
25. Yamagishi K, Aleksic N, Hannan PJ, Folsom AR; ARIC Study Inverstigators. Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. J Atheroscler Thromb. 2010;17(4):402-409.
26. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010;116(4):529-536.
27. Montes R, Paramo JA, Angles-Cano E, Rocha E. Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma. Br J Haematol. 1996;92(4):979-985. (Pubitemid 26111171)
28. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(3):493-498. (Pubitemid 29135146)
29. The International HapMap Consortium. The International HapMap Project. Nature. 2003; 426(6968):789-796.
30. Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-2948. (Pubitemid 350162903)